Tumor necrosis factor alpha as a marker of systemic and local inflammation in “healthy” smokers by Diez-Pina, Juan M et al.
© 2009 Diez-Pina et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of General Medicine 2009:2 9–14 9
ORIGINAL RESEARCH
Tumor necrosis factor alpha as a marker of systemic 
and local inﬂ  ammation in “healthy” smokers
Juan M Diez-Pina1
María J Fernandez-Aceñero3
María J Llorente-Alonso2
Salvador Diaz-Lobato4
Sagrario Mayoralas1
Asuncion Florez1
1Department of Pneumology; 
2Department of Biochemistry, 
Hospital de Móstoles, Móstoles, 
Madrid, Spain; 3Department 
of Pathology, Fundacíon 
Jiménez-Díaz, Madrid, Spain; 
4Department of Pneumology, Hospital 
Ramón y Cajal, Madrid, Spain
Correspondence: Juan M Diez-Pina
Neumología, Hospital de Móstoles, 
Móstoles, Madrid, Spain
Email jmdpas@hotmail.com
Background: Tobacco smoking induces a local and systemic inﬂ  ammatory reaction and also 
a decline in pulmonary function. There are some novel noninvasive methods to measure the 
degree of inﬂ  ammatory bronchial reaction, including the exhaled breath condensate (EBC) in 
which several inﬂ  ammatory markers can be measured, including tumor necrosis factor alpha 
(TNF-α). There is a clear clinical need to develop methods that allow early detection of smokers 
at risk of losing pulmonary function.
Objectives: The aims of the present study are: 1) to show that smokers show higher levels of 
TNF-α both in serum and EBC; 2) to analyze the possible inﬂ  uence of gender, age, and weight 
on this parameter; and 3) to determine a possible association between smoking and pulmonary 
function parameters and TNF-α levels.
Material and methods: We have prospectively analyzed two cohorts of smokers and non-
smokers subjects without any chronic or acute disease (within eight weeks of study initiation). 
We have performed pulmonary function tests with bronchodilators and also collected EBC and 
blood samples before smoking cessation. Statistical analysis was performed with SPSS 11.0 
for Windows Statistical Package.
Results: The study has enrolled 17 patients (8 smokers), 50% of whom were females. Mean age 
was 38.59 years old (standard deviation, 7.4). The mean number of cigarettes smoked in the smoker 
group was 26.14 (11.29) cigarettes/day and the mean age when tobacco ﬁ  rst began was 15.14 (2.04) 
years. We have not been able to show any signiﬁ  cant differences in TNF-α levels according to age 
or weight. For the whole series we have not found any signiﬁ  cant inﬂ  uence of gender in TNF-α 
levels, but after dividing the series in smokers and nonsmokers, we have shown higher levels of 
TNF-α in serum (5.59 [0.26] pg/mL vs 5.56 [0.37] pg/mL; nonsigniﬁ  cant [NS]) and EBC (4.94 
[0.41] pg/mL vs 4.22 [0.36] pg/mL; p = 0.031) in male smokers. On the other hand, nonsmoking 
females showed slightly higher TNF-α levels in serum (5.70 [0.50] pg/mL vs 5.42 [0.29] pg/mL; 
NS) and EBC (4.54 [0.92] vs 4.11 [0.41 pg/mL]; NS). Smokers had higher TNF-α levels in EBC 
(4.46 [0.58] pg/mL vs 4.34 [0.62] pg/mL; NS), while serum TNF-α levels were slightly higher in 
nonsmokers (5.52 [0.56] pg/mL vs 5.50 [0.27] pg/mL; NS). We have not demonstrated any associa-
tion between tobacco consumption and TNF-α levels. We have not shown any signiﬁ  cant relation 
between pulmonary function and the studied parameters, with only a modest association between 
forced expiratory volume at one second and forced vital capacity and TNF-α levels in EBC.
Conclusion: Smokers show higher TNF-α levels in EBC. Among smokers, males show higher 
levels of TNF in serum and EBC. We have not conﬁ  rmed any signiﬁ  cant inﬂ  uence of age or 
weight on TNF-α levels. These levels do not seem to be inﬂ  uenced either by the amount of 
tobacco or the time since habit began. We have shown a modest relation between pulmonary 
function and TNF-α levels in EBC.
Keywords: inﬂ  ammatory markers, tumor necrosis factor, exhaled breath condensate, cigarette 
smoking
Introduction
Oxidative stress is a basic component of the airways inﬂ  ammatory reaction in 
patients with chronic obstructive pulmonary disease (COPD). Its pathogenesis seems International Journal of General Medicine 2009:2 10
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to be related to the loss of balance between oxidants and 
antioxidants.1 Oxidative stress seems to be augmented in 
healthy smokers and tobacco smoking is the main risk factor 
for the development of COPD.2
Traditional methods to collect samples from the lower 
airways include induced sputum and bronchoscopy with 
bronchoalveolar lavage (BAL). There are not many non-
invasive methods to measure inﬂ  ammatory reaction in the 
airways. In recent years there has been a growing interest 
in the use of exhaled breath condensate (EBC), which is a 
noninvasive method that allows repeated sample collection.3,4 
The condensate is supposed to reﬂ  ect the composition of the 
bronchoalveolar extracellular ﬂ  uid, in which there are some 
nonvolatile substances and up to 200 volatile ones.5,6 Among 
the nonvolatile molecules we can ﬁ  nd in the condensate we 
can mention proteins, lipids, oxidants, and nucleotides. To 
measure these substances we ﬁ  rst cool the exhaled breath to 
obtain a condensate. The molecules we measure are mark-
ers for different pulmonary disorders. Among the different 
markers of oxidative stress and/or inﬂ  ammatory mediators 
that have been measured in the EBC of healthy subjects and 
also in patients with different kind of airway disorders, we 
can mention 8-isoprostane, leukotrienes, and prostaglandins. 
Nevertheless, this technique is still associated with some 
difﬁ  culties for sample collection and also for the analysis 
and interpretation of the exhaled breath condensate, which 
should be taken into account.3,7
Cytokines act as signalling molecules in the immune 
system and also in other body systems, as part of a complex 
network participating in the immune response. Several pro-
inﬂ  ammatory cytokines have been detected in the BAL ﬂ  uid 
(IL-1β, TNF-α), and also neutrophile chemotactic cytokines 
(IL-8) and anti-inﬂ  ammatory cytokines (IL-10).8 The same 
kind of cytokines have been also found in the EBC of healthy 
subjects, but they have been different from those reported in 
patients with pulmonary inﬂ  ammatory disorders.9
Tumor necrosis factor alpha (TNF-α) is a powerful proin-
ﬂ  ammatory cytokine, considered important for neutrophiles 
recruitment, that is elevated in COPD patients.10,11 Systemic 
hypoxemia is associated with the activation of the TNF-α 
system in COPD patients and this cytokine has been reported 
as an important etiopathogenic factor in the lung damage 
secondary to smoking.12
There is a clinical need to ﬁ  nd novel markers of early 
inﬂ  ammatory change that allow detection of the population 
at risk of developing pulmonary disorders, so that preventive 
measures can be initiated before irreversible damage has 
taken place. The aim of the present study is to show whether 
“healthy” smokers show higher levels of local and systemic 
inﬂ  ammatory markers as compared with nonsmokers and also 
to analyze the possible inﬂ  uence of antropometric features, 
tobacco consumption, and pulmonary function values on 
these markers.
Material and methods
We have designed an observational analytical prospective 
cohort study with two cohorts: one of healthy smokers and 
another of healthy nonsmokers. The study group enrolled 
smokers that were consulted for the ﬁ  rst time in our smoking 
cessation clinic and the comparison group corresponded to 
healthy hospital workers that had never smoked. We obtained 
written signed consent from all the subjects participating in 
the study. This study was approved by the Ethical Commit-
tee of our Hospital.
In both groups we obtained a thorough history, including 
prescription drug consumption and also a physical examina-
tion. The inclusion criteria for our study were absence of any 
previous disease or regular use of drugs in the eight weeks 
prior to the study initiation. In the smokers group we dis-
carded mainly signs and symptoms suggestive of a chronic 
bronchitis and/or bronchial hyperreactivity. Patients that 
fulﬁ  lled inclusion criteria underwent a forced spirometry 
(Jaeger MS Body/diff Master Screen; Jaeger, Hoechberg, 
Germany) following the recommendations set forth by differ-
ent authors, in order to conﬁ  rm that pulmonary function was 
normal. We also performed pulmonary function tests after 
bronchodilatation with salbutamol to exclude reversibility, 
according to previously established criteria.13
We have collected a sample of exhaled breath and blood; 
in the smokers these samples were collected before giving up 
tobacco consumption. To collect the EBC we have employed 
a commercially-available condenser (Ecoscreen; Jaeger). All 
the collections were performed under the same conditions of 
temperature and humidity. Smokers refrained from smoking 
8–10 hours before the collection. The patients were asked to 
take several breaths at tidal volume without nose clipping, 
inspirating and exhaling the air through the mouth, for 15–20 
minutes or until total volume reached 200 ml.
The serum and exhaled breath samples were kept at −70 °C 
until analysis. TNF-α was determined in both ﬂ  uids with 
ELISA immunoassay (DRG Diagnostics GMBH, Germany). 
We have employed different monoclonal antibodies against 
different epitopes in the TNF-α molecule. The anti-TNF-α 
conjugate was labelled with horseradish peroxidase (HRP), 
a TRIS maleate buffer with bovine albumin, EDTA and 
timol. Tetramethylbenzidine in dimethylformamide (TMB) International Journal of General Medicine 2009:2 11
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was used as chromogen. TNF-α level is proportional to the 
intensity of the color generated in this reaction and is esti-
mated by interpolating the value in the calibration curve to 
5 points. We have performed a bichromatic reading of the 
microtiter plate at 450 nm comparing it against a reference 
ﬁ  lter of 620 nm. The assay was automatized in DSX (Dynex 
Technology, Chantilly, VA, USA).
The results of the study were analyzed with SPSS 11.0 for 
Windows Statistical Analysis Package (SPSS Inc., Chicago, 
IL, USA). After verifying normality of the distribution with 
Kolmogorov–Smirnov test, descriptive statistics included 
mean (standard deviation) for parametric quantitative vari-
ables or median (range) for nonparametric ones. Qualitative 
variables were described with absolute numbers and percent-
ages. Bivariate analysis include Student’s t test or ANOVA 
for mean comparison or their corresponding nonparametric 
tests (Mann–Whitney’s U or Kruskall–Wallis test). Asso-
ciation between qualitative variables was analysed with the 
squared-chi test. Correlation between quantitative variables 
was analyzed with Pearson’s r for parametric ones and 
Spearman’s rho for nonparametric ones. The signiﬁ  cance 
value was set in all the cases at a p  0.05 value.
For the graphic representation of our data we have chosen 
the box-plot diagram, representing the median and the 25th 
and 75th percentile values for the variables in the central box 
and outlier variables.
Results
We enrolled 17 patients in this study. Table 1 summarizes 
the demographic features of these patients and also the data 
related to pulmonary function. Smokers had a mean cigarette 
consumption of 26.14 cigarettes per day (SD: 11.29); the 
mean age when smoking ﬁ  rst began was 15.14 (SD: 2.03) 
and the mean cumulative consumption index was 37.43 
(17.28) packages/year.
We did not ﬁ  nd differences in TNF-α levels in EBC 
between smokers and nonsmokers (4.46 [0.58] pg/mL vs 4.34 
[0.62] pg/mL). TNF-α levels in serum did not show either 
differences between the two groups (5.52 [0.56] pg/mL vs 
5.50 [0.27] pg/mL) (Figure 1).
When we compared the TNF-α levels between genders 
(without considering whether they smoked) we did not 
ﬁ  nd any signiﬁ  cant differences in any of the parameters 
(Figure 2). We did not find any significant association 
either between TNF-α levels in both kind of samples and the 
patients’ age or weight.
Table 1 Demographic features of the control and study group.   The 
numbers correspond to mean (standard deviation)
Smokers Nonsmokers p value
N: 17 8 9
Age (years) 43.57 (5.68) 35.10 (6.56) 0.015
Gender Male: 4 Male: 5 0.52
Female: 4 Female: 4
Weight (kg) 79.01 (27.60) 73.56 (16.56) 0.63
BMI (kg/m2) 27.78 (6.67) 24.72 (3.27) 0.30
FVC (ml) 4232.86 (992.77) 4778.89 (924.76) 0.275
FVC (%) 99.77 (13.50) 97.42 (9.96) 0.694
FEV1 (ml) 3424.29 (777.28) 4015.56 (669.68) 0.124
FEV1 (%) 104.60 (16.97) 104.21 (10.59) 0.95
FEV1/FVC 81.31 (5.16) 84.41 (4.23) 0.207
Abbreviations: BMI, body mass index; FEV1, forced respiratory volume in one second; 
FVC, forced vital capacity.
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Figure 1 Tumor necrosis factor alpha (TNF-α) levels in serum and exhaled breath 
condensate (EBC) in smokers and nonsmokers.International Journal of General Medicine 2009:2 12
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However, when we divided our series in two groups 
according to the smoking habits of the patients, we found that 
male smokers had higher TNF-α levels than male nonsmok-
ers in EBC (4.94 [0.41] vs 4.22 [0.36] pg/mL; p = 0.031), 
but not in serum (5.59 [0.26] vs 5.56 [0.37] pg/mL; NS dif-
ference). On the other hand, no differences were found for 
nonsmoker females in TNF-α levels in serum (5.70 [0.50] 
vs 5.42 [0.29] pg/mL; NS) nor in EBC (4.54 [0.92] vs 4.11 
[0.41] pg/mL; NS) (Figure 3).
When we analyzed the possible association with 
pulmonary function parameters, we found only an statistically 
signiﬁ  cant association between porcentual values of the 
forced vital capacity (FVC) and forced respiratory volume 
in one second (FEV1) and mean TNF-α levels in EBC for 
the whole series (r values = –0.41 and –0.45, with p values 
for the correlations 0.031 and 0.013, respectively). When 
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Figure 2 Tumor necrosis factor alpha (TNF-α) in serum and exhaled breath con-
densate (EBC) in both genders.
we considered for the analysis whether the patients smoked, 
we found that in the control group no TNF-α levels was 
signiﬁ  cantly associated with tests measuring lung function. 
In the study group we found a trend toward signiﬁ  cance for 
the possible association between TNF-α levels in EBC and 
FEV1 and FVC (r = –0.074 and 0.70 with p = 0.058 and 0.079, 
respectively) (Table 2).
In the study group we have also analyzed the inﬂ  uence 
of tobacco consumption (number of cigarettes a day and age 
at consumption initiation) and TNF-α levels, but we did not 
ﬁ  nd any signiﬁ  cant association between these parameters 
(r values 0.46 and 0.138 for EBC and r values 0.94 and 0.52 
for serum TNF-α with p  0.05, respectively).
Discussion
Cigarette smoking increases the intensity of oxidative stress, 
eventually leading to COPD. It would be necessary to measure 
the magnitude of local and systemic inﬂ  ammation before an 
irreversible reduction of pulmonary function has taken place, 
for this could allow early identiﬁ  cation of the patients at risk 
and also earlier and more energetic preventive interventions 
oriented toward tobacco cessation. Several reports have com-
pared the levels of different inﬂ  ammatory molecules, including 
TNF-α levels, in the EBC of smokers and nonsmokers.5,14,15
The techniques used to measure the intensity of inﬂ  am-
matory reaction in the distal airways have all been invasive 
until recent years. The use of EBC has allowed a noninvasive 
analysis of the composition of the ﬂ  uid layer of the airways. 
However, this technique is still associated with some dif-
ﬁ  culties that hamper widespread use as a diagnostic tool for 
everyday practice, including lack of reproducibility, vari-
ability, possible inﬂ  uence of external factors (alcohol, smok-
ing, drugs) and the difﬁ  culty to measure some substances 
present in the EBC after freezing. Besides, there are still 
no established reference values for the different parameters 
in the normal population or in patients with different lung 
disorders and yet there have been no studies that analyze the 
possible relation between altered levels of the inﬂ  ammatory 
parameters and different symptoms or pulmonary function 
tests or the possible inﬂ  uence of different drugs on these 
inﬂ  ammatory markers.4,16,17
Several volatile and nonvolatile substances that can serve 
to estimate the intensity of the local inﬂ  ammatory reaction 
have been detected in samples from the EBC. One of them is 
TNF-α, a proinﬂ  ammatory cytokine that seems to be implied 
in pulmonary damage associated with smoking.
In our study we have found that serum TNF-α levels are 
not signiﬁ  cantly different between smokers and nonsmokers, International Journal of General Medicine 2009:2 13
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although they are slightly higher in nonsmokers. Vernooy 
and colleagues did not ﬁ  nd either any signiﬁ  cant differences 
in serum TNF-α levels between control patients and smokers 
with established COPD.18 Ryder and colleagues compared 
two groups of smokers and nonsmokers and exposed blood 
mononuclear cells from these groups to tobacco acutely in 
vitro, to subsequently measure the levels of TNF-α and other 
inﬂ  ammatory markers. In this series the serum TNF-α levels 
were also higher in nonsmokers, as we have also shown, but 
again this difference did not reach signiﬁ  cance.19 A possible 
explanation for this ﬁ  nding comes from a report by Mian and 
colleagues who showed an inhibitory effect of smoking on 
TNF-α production in vitro, that can be reversible.20
In our series the EBC TNF-α levels were higher in 
smokers; our results are in agreement with those reported 
by other authors in the literature. Sack and colleagues com-
pared in one report the TNF-α levels in healthy smokers 
and nonsmokers and also in a group of patients with acute 
pulmonary distress due to severe pneumonia ventilated in 
the intensive care unit. These authors showed that TNF-α 
levels (and also other inﬂ  ammatory cytokines, like IL-8 and 
IL-1) were higher in the ventilated patients compared with 
the other two groups. Besides, smokers had higher TNF-α 
levels in EBC than nonsmokers.9 Garey and colleagues have 
reported a study similar to ours in which they also conﬁ  rm 
signiﬁ  cantly higher TNF-α levels in the EBC of healthy 
smokers (7.4 vs 3.9 pg/mL).14
The aforementioned studies have not analyzed the pos-
sible inﬂ  uence of tobacco consumption on these inﬂ  amma-
tory parameters in the smoker group. In our study we have 
not found that the magnitude of tobacco consumption has 
any inﬂ  uence on these inﬂ  ammatory markers. Those studies 
have not analyzed either the relation between TNF-α levels 
in EBC and lung function parameters. One of the ﬁ  ndings in 
our group of patients was a signiﬁ  cant association between 
TNF-α levels in EBC and some pulmonary function tests, 
such as measuring the percentage of FEV1 and FVC.
Our group has also studied possible associations 
between age, gender or weight and TNF-α levels and 
our results are slightly different from those reported 
Figure 3 Tumor necrosis factor alpha (TNF-α) in serum and exhaled breath condensate (EBC) in male/female considering the smoking status.
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Table 2 Association between lung function parameters and TNF-α 
levels in serum and EBC
Number Mean value Signiﬁ  cance
TNF-α serum
 Smokers 8 5.50 N.  S.
 Nonsmokers 9 5.52
TNF-α EBC
 Smokers 8 4.46 N.  S.
 Nonsmokers 9 4.34
FVC ml
 Smokers 8 4232.86 N.  S.
 Nonsmokers 9 4778.89
FVC %
 Smokers 8 99.77 0.079
 Nonsmokers 9 97.42
FEV1 ml
 Smokers 8 3424.29 N.  S.
 Nonsmokers 9 4015.56
FEV1 %
 Smokers 8 104.60 0.058
 Nonsmokers 9 104.21
FEV1/FVC
 Smokers 8 81.31 N.  S.
 Nonsmokers 9 84.41
Abbreviations: EBC, exhaled breath condensate; FEV1, forced respiratory volume in 
one second; FVC, forced vital capacity; TNF-α, tumor necrosis factor alpha.
in the literature. Himmerich et al showed in one report 
a signiﬁ  cant inﬂ  uence of age on the serum TNF-α levels 
(increasing with age), but in our series we have not con-
ﬁ  rmed their ﬁ  ndings. However, we must acknowledge that 
our control group is signiﬁ  cantly younger than the study one 
and this can limit results interpretation. In the same report, 
Himmerich and colleagues also conﬁ  rmed an association 
between weight and TNF-α levels that we have not been 
able to conﬁ  rm, and a slight inﬂ  uence of gender on the 
serum TNF-α levels, similar to the one we have found in 
our patients. Nevertheless, these authors did not measure 
TNF-α levels in EBC.
We can conclude that EBC is a potential useful tool 
for the determination of inﬂ  ammatory parameters in distal 
airways. TNF-α levels can be one of the important parameters 
we can use. However, further studies with larger number 
of patients are needed to conﬁ  rm the results found in the 
present study.
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